PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

29.34USD+1.11 (+3.93%)Market Closed

Market Summary

USD29.34+1.11

Market Closed

3.93%

PTGX Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

PTGX Stock Price

View Fullscreen

PTGX RSI Chart

PTGX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

10.62

Price/Sales (Trailing)

28.68

EV/EBITDA

-10.59

Price/Free Cashflow

-26.82

PTGX Price/Sales (Trailing)

PTGX Profitability

EBT Margin

-212.32%

Return on Equity

28.93%

Return on Assets

25.76%

Free Cashflow Yield

-3.73%

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

60.0M

Rev. Growth (Yr)

200%

Rev. Growth (Qtr)

50%

PTGX Earnings

Earnings (TTM)

162.1M

Earnings Growth (Yr)

714.8%

Earnings Growth (Qtr)

658.51%

Breaking Down PTGX Revenue

Last 7 days

12.6%

Last 30 days

8.5%

Last 90 days

8.7%

Trailing 12 Months

15.7%

How does PTGX drawdown profile look like?

PTGX Financial Health

Current Ratio

15.72

PTGX Investor Care

Shares Dilution (1Y)

2.45%

Diluted EPS (TTM)

2.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	43.3M	0	0	60.0M
2022	46.9M	45.5M	35.2M	26.6M
2021	31.2M	27.2M	24.4M	27.4M
2020	20.0M	22.8M	25.7M	28.6M
2019	21.7M	0	14.2M	17.1M
2018	31.3M	42.5M	39.9M	30.9M
2017	0	0	0	20.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Protagonist Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	ali asif	sold	-30,985	25.11	-1,234	chief financial officer
Apr 01, 2024	patel dinesh v ph d	sold	-707,750	28.31	-25,000	president and ceo
Mar 07, 2024	selick harold e	acquired	12,266	1.89	6,490	-
Mar 01, 2024	patel dinesh v ph d	sold	-948,600	31.62	-30,000	president and ceo
Mar 01, 2024	waddill william d.	acquired	79,017	6.09	12,975	-
Mar 01, 2024	ali asif	acquired	146,040	12.17	12,000	chief financial officer
Mar 01, 2024	ali asif	sold	-459,318	32.2374	-14,248	chief financial officer
Mar 01, 2024	waddill william d.	sold	-406,636	31.34	-12,975	-
Feb 29, 2024	ali asif	sold	-305,048	30.692	-9,939	chief financial officer
Feb 26, 2024	patel dinesh v ph d	sold (taxes)	-322,320	29.53	-10,915	president and ceo

Which funds bought or sold PTGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Campbell & CO Investment Adviser LLC	new	-	398,164	398,164	0.03%
May 10, 2024	BlackRock Inc.	added	0.46	34,003,500	161,125,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	84.4	491,432	861,912	-%
May 10, 2024	Jackson Creek Investment Advisors LLC	new	-	1,004,000	1,004,000	0.36%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	820,542	820,542	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	620,520	620,520	0.05%
May 10, 2024	VANGUARD GROUP INC	added	1.24	20,053,400	92,372,600	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	unchanged	-	36.00	174	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	32,199	32,199	-%
May 10, 2024	Hillsdale Investment Management Inc.	new	-	5,786	5,786	-%

Are Funds Buying or Selling PTGX?

Are funds buying PTGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTGX

No. of Funds

Unveiling Protagonist Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	5.4%	3,120,957	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.2%	5,315,514	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	4.5%	2,613,453	SC 13G/A
Feb 13, 2024	vanguard group inc	5.47%	3,153,916	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	2.24%	1,291,701	SC 13G/A
Feb 02, 2024	farallon capital partners, l.p.	0.7%	386,653	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	5,543,902	SC 13G/A
Jan 23, 2024	state street corp	4.73%	2,729,929	SC 13G/A
Dec 18, 2023	point72 asset management, l.p.	5.5%	3,186,077	SC 13G

Recent SEC filings of Protagonist Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading
Apr 12, 2024	PRE 14A	PRE 14A
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 11, 2024	4	Insider Trading

Peers (Alternatives to Protagonist Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Protagonist Therapeutics Inc News

Latest updates

Protagonist Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	50.0%	254,953,000	169,968,667	84,984,333	-	-	859,000	25,722,000	8,617,000	10,286,000	2,265,000	6,189,000	5,650,000	13,114,000	6,217,000	3,647,000	3,894,000	4,141,000	1,560,000	2,353,000	6,117,000	11,674,000
Operating Expenses	31.6%	48,644,000	36,951,000	36,021,000	36,516,000	32,303,000	42,302,000	46,833,000	45,633,000	44,212,000	33,147,000	30,210,000	24,480,000	20,886,000	24,434,000	23,344,000	20,018,000	21,308,000	16,208,000	17,765,000	15,506,000	20,913,000
S&GA Expenses	-100.0%	-	8,052,000	8,605,000	6,632,000	6,901,000	7,691,000	10,515,000	7,260,000	7,256,000	6,715,000	5,965,000	4,994,000	4,891,000	4,177,000	4,576,000	4,107,000	4,015,000	3,764,000	3,516,500	3,361,000	3,178,000
R&D Expenses	16.7%	33,734,000	28,899,000	27,416,000	29,884,000	25,402,000	34,611,000	36,318,000	38,373,000	36,956,000	26,432,000	24,245,000	19,486,000	15,995,000	20,257,000	18,768,000	15,911,000	17,293,000	12,444,000	14,248,500	12,145,000	17,735,000
EBITDA Margin	0.0%	-2.11	-2.11	-2.92	-4.75	-3.54	-2.74	-2.66	-4.56	-4.35	-2.94	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	127,000	19,000	209,000	243,000	-	-	-	-	-	-
Income Taxes	-	3,326,000	-	-	-	-	-	-	-	-	-	-	2,500	-	1,129,000	176,000	841,000	-100,000	183,000	-799,000	-	-
Earnings Before Taxes	-	210,666,000	-	-33,725,000	-	-	-	-	-36,907,000	-33,804,000	-30,842,000	-23,998,000	-18,886,000	-7,763,000	-18,292,000	-19,904,000	-16,644,500	-16,511,000	-13,920,000	-14,664,000	-8,735,000	-8,663,000
EBT Margin	0%	-2.12	-2.12	-2.94	-4.79	-3.57	-2.76	-2.68	-4.59	-4.41	-2.99	-	-	-	-	-	-	-	-	-	-	-
Net Income	658.5%	207,340,000	27,335,000	-33,725,000	-34,194,000	-31,232,000	-41,037,000	-20,930,000	-36,907,000	-33,804,000	-30,842,000	-23,998,000	-18,886,000	-7,763,000	-19,421,000	-20,080,000	-17,501,000	-16,409,000	-14,103,000	-13,865,000	-8,735,000	-8,663,000
Net Income Margin	305.3%	2.70	-1.32	-3.24	-4.79	-3.70	-2.92	-2.61	-4.59	-4.41	-2.99	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-263.3%	-27,671,000	16,941,000	-34,357,000	-31,705,000	-25,363,000	-13,925,000	-37,939,000	-27,135,000	-28,735,000	-24,200,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	75.8%	629	358	330	320	240	248	282	311	348	348	373	404	298	324	217	225	135	155	155	148	132
Current Assets	76.5%	628	356	325	317	236	243	277	304	342	341	328	372	286	316	204	217	126	145	144	137	123
Cash Equivalents	-7.5%	173	187	231	235	128	126	153	120	98.00	124	121	192	83.00	118	84.00	146	60.00	33.00	50.00	71.00	70.00
Net PPE	-7.0%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	223.5%	69.00	21.00	28.00	26.00	24.00	32.00	39.00	43.00	47.00	48.00	44.00	47.00	39.00	45.00	48.00	57.00	72.00	75.00	59.00	64.00	31.00
Current Liabilities	87.6%	40.00	21.00	28.00	26.00	23.00	31.00	37.00	40.00	43.00	44.00	39.00	43.00	35.00	40.00	39.00	35.00	36.00	35.00	31.00	33.00	24.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	10.00	-	-	-
Shareholder's Equity	66.5%	560	337	302	294	216	216	244	268	302	300	330	357	259	280	170	167	63.00	80.00	95.00	84.00	101
Retained Earnings	33.7%	-408	-615	-643	-608	-570	-536	-502	-471	-430	-409	-372	-338	-307	-283	-264	-257	-237	-217	-200	-183	-154
Additional Paid-In Capital	1.7%	969	952	945	903	787	753	747	740	733	710	702	696	567	563	435	425	300	298	296	268	256
Shares Outstanding	1.5%	59.00	58.00	58.00	57.00	51.00	49.00	49.00	49.00	49.00	46.00	46.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,600	-	-	-	379,500	-	-	-	2,100	-	-	-	641	-	-	-	212	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-261.7%	-27,429	16,960	-26,611	-26,238	-34,347	-31,635	-25,201	-13,635	-37,666	-26,939	-28,470	-23,700	-28,756	-18,867	-16,287	-21,482	-15,848	-14,289	-14,246	3,670	-16,662
Share Based Compensation	41.7%	9,352	6,601	6,765	8,343	7,584	5,512	5,950	6,805	5,935	5,024	4,775	3,936	2,660	1,967	1,888	1,996	2,048	2,160	2,201	2,013	1,979
Cashflow From Investing	109.9%	6,071	-61,287	-13,559	25,762	9,826	3,935	57,275	34,734	-4,476	27,867	-44,707	7,773	-6,793	-74,402	-54,122	-5,171	42,730	-12,554	-32,039	-13,225	4,108
Cashflow From Financing	1266.0%	7,199	527	35,315	108,172	26,463	553	680	680	16,925	2,173	1,381	125,390	979	126,981	7,669	112,577	399	9,779	25,237	10,630	390

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PTGX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Consolidated Statements of Operations
License and collaboration revenue	$ 254,953	$ 0
Revenue from Contract with Customer, Product and Service [Extensible List]	License and Collaboration Agreement	License and Collaboration Agreement
Operating expenses:
Research and development	$ 33,734	$ 27,416
General and administrative	14,910	8,605
Total operating expenses	48,644	36,021
Income (loss) from operations	206,309	(36,021)
Interest income	4,376	2,491
Other expense, net	(19)	(195)
Income (loss) before income tax expense	210,666	(33,725)
Income tax expense	(3,326)	0
Net income (loss)	$ 207,340	$ (33,725)
Net income (loss) per share, basic	$ 3.41	$ (0.67)
Net income (loss) per share, diluted	$ 3.26	$ (0.67)
Weighted-average shares used to compute net income (loss) per share, basic	60,855,689	50,573,650
Weighted-average shares used to compute net income (loss) per share, diluted	63,595,328	50,573,650

PTGX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 172,568	$ 186,727
Marketable securities	150,067	154,890
Receivable from collaboration partner	300,043	10,000
Prepaid expenses and other current assets	4,875	3,960
Total current assets	627,553	355,577
Property and equipment, net	1,111	1,195
Restricted cash - noncurrent	225	225
Operating lease right-of-use asset	387	954
Total assets	629,276	357,951
Current liabilities:
Accounts payable	3,507	772
Payable to collaboration partner	3	3
Accrued expenses and other payables	16,487	19,358
Deferred revenue - current	16,125
Income taxes payable	3,326
Operating lease liability - current	462	1,141
Total current liabilities	39,910	21,274
Deferred revenue, noncurrent	28,922
Total liabilities	68,832	21,274
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.00001 par value, 90,000,000 shares authorized; 58,600,787 and 57,708,613 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	969,042	952,491
Accumulated other comprehensive loss	(229)	(105)
Accumulated deficit	(408,370)	(615,710)
Total stockholders' equity	560,444	336,677
Total liabilities and stockholders' equity	$ 629,276	$ 357,951

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

CEO	Dr. Dinesh V. Patel Ph.D.
WEBSITE	protagonist-inc.com
INDUSTRY	Biotechnology
EMPLOYEES	106

Protagonist Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protagonist Therapeutics Inc? What does PTGX stand for in stocks?

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagonist Therapeutics Inc (PTGX)?

As of Mon May 13 2024, market cap of Protagonist Therapeutics Inc is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers. The fair value of Protagonist Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protagonist Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protagonist Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

What is Protagonist Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, PTGX's PE ratio (Price to Earnings) is 10.62 and Price to Sales (PS) ratio is 28.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.